Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma

Leukemia & Lymphoma
Dina IbrahimAyad Al-Katib

Abstract

High-dose chemotherapy with autologous marrow or stem cell rescue (HDC/ASCT) is an effective strategy in patients with relapsed Hodgkin lymphoma. Various chemotherapy regimens have been used for cytoreduction prior to HDC/ASCT. In this study, our objective was to determine the response rate to PEND in a group of patients with relapsed Hodgkin lymphoma. Nineteen patients with relapsed or primary refractory Hodgkin lymphoma underwent treatment with the PEND regimen and received a median of 2 cycles (1 - 6 cycles). The PEND regimen builds on our prior results with ABDIC and consists of prednisone 40 mg/m2 orally (PO) daily x 5 days; etoposide 50 mg/m2 PO daily x 14 days; mitoxantrone 5 mg/m2/d IV, days 1 and 3; and DTIC 200 mg/m2/d intravenous continuous infusion (CIV) over 24 h, days 1 to 5, via central venous catheter. The treatment was given every 28 days. There were 3 complete responses (16%) and 10 partial responses (53%) yielding a total response rate of 69% (95% C.I. 43%, 87%). Myelosuppression was the predominant toxicity; no deaths were due to toxicity. After achieving maximum response to PEND, 10 eligible patients received a consolidative treatment with HDC/ASCT. All 6 patients who did not respond to PEND died from disea...Continue Reading

References

Nov 19, 1992·The New England Journal of Medicine·G P CanellosB A Peterson
Dec 1, 1991·The American Journal of Medicine·J O ArmitageD T Purtilo
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·M A RichardsT A Lister
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BodisJ Thomas
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
Oct 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A JostingUNKNOWN Participating Centers
Apr 19, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ConstansUNKNOWN GEL/TAMO Cooperative Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.